[{"id":"264b6c87-54a5-4e3b-9928-8b444e1c65f6","acronym":"ROYAL","url":"https://clinicaltrials.gov/study/NCT07151911","created_at":"2025-09-06T13:40:25.560Z","updated_at":"2025-09-06T13:40:25.560Z","phase":"","brief_title":"Real wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer Patients","source_id_and_acronym":"NCT07151911 - ROYAL","lead_sponsor":"Azienda Ospedaliero-Universitaria di Modena","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/26/2024","start_date":" 08/26/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2031","study_completion_date":" 09/01/2031","last_update_posted":"2025-09-03"},{"id":"17de40db-c7f4-4c4a-854e-574167dd0b13","acronym":"APEAK","url":"https://clinicaltrials.gov/study/NCT06947811","created_at":"2025-06-07T14:40:16.432Z","updated_at":"2025-06-07T14:40:16.432Z","phase":"Phase 1/2","brief_title":"A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations","source_id_and_acronym":"NCT06947811 - APEAK","lead_sponsor":"Sun Yat-sen University","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Ameile (aumolertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 06/09/2025","start_date":" 06/09/2025","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-06-04"},{"id":"7a55dd21-17fa-4758-9f8c-76ac780a7858","acronym":"","url":"https://clinicaltrials.gov/study/NCT04750928","created_at":"2021-02-11T12:52:56.866Z","updated_at":"2025-02-25T12:27:56.800Z","phase":"Phase 1/2","brief_title":"Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas","source_id_and_acronym":"NCT04750928","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 11/29/2021","start_date":" 11/29/2021","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-02-24"},{"id":"fb4d840f-ccf1-4e5e-ac00-2c10191c007e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554367","created_at":"2022-09-26T14:56:10.119Z","updated_at":"2025-02-25T13:54:43.263Z","phase":"Phase 2","brief_title":"Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554367","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • NRAS • HRAS • RAS","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12","tags":["KRAS • BRAF • NRAS • HRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Mektovi (binimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 199","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 08/26/2026","primary_completion_date":" 08/26/2026","study_txt":" Completion: 08/26/2026","study_completion_date":" 08/26/2026","last_update_posted":"2025-02-20"},{"id":"be1e3182-1b8c-4aa1-8e6a-90c8411f7afc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05996107","created_at":"2023-08-16T16:08:40.965Z","updated_at":"2025-02-25T14:03:44.386Z","phase":"Phase 1","brief_title":"Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT05996107","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/27/2024","start_date":" 02/27/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2030","study_completion_date":" 06/01/2030","last_update_posted":"2025-02-19"},{"id":"15fc70e8-4f11-459e-b3ee-4470ced3ad18","acronym":"EPIK-B5","url":"https://clinicaltrials.gov/study/NCT05038735","created_at":"2021-09-09T13:53:04.798Z","updated_at":"2025-02-25T14:16:18.971Z","phase":"Phase 3","brief_title":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.","source_id_and_acronym":"NCT05038735 - EPIK-B5","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER • PIK3CA","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • fulvestrant"],"overall_status":"Recruiting","enrollment":" Enrollment 234","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/29/2027","study_completion_date":" 12/29/2027","last_update_posted":"2025-02-18"},{"id":"09faeec2-6d19-4e99-bfa8-ce9ad5372038","acronym":"","url":"https://clinicaltrials.gov/study/NCT05843253","created_at":"2023-05-06T15:04:11.203Z","updated_at":"2025-02-25T14:09:40.595Z","phase":"Phase 2","brief_title":"Study of Ribociclib and Everolimus in HGG and DIPG","source_id_and_acronym":"NCT05843253","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C","pipe":" | ","alterations":" PIK3CA mutation • CDKN2A deletion","tags":["PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CDKN2A deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/22/2024","start_date":" 08/22/2024","primary_txt":" Primary completion: 08/28/2028","primary_completion_date":" 08/28/2028","study_txt":" Completion: 08/28/2034","study_completion_date":" 08/28/2034","last_update_posted":"2025-02-17"},{"id":"38d96c78-7695-48ef-a4bd-d1c77b87723e","acronym":"NCI-2018-01050","url":"https://clinicaltrials.gov/study/NCT03774472","created_at":"2021-01-18T18:40:19.361Z","updated_at":"2025-02-25T14:15:17.560Z","phase":"Phase 1/2","brief_title":"Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT03774472 - NCI-2018-01050","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 08/20/2018","start_date":" 08/20/2018","primary_txt":" Primary completion: 04/17/2024","primary_completion_date":" 04/17/2024","study_txt":" Completion: 04/17/2024","study_completion_date":" 04/17/2024","last_update_posted":"2025-02-17"},{"id":"624dd6dc-cc83-4a6f-bc36-82aa836ef4f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05429502","created_at":"2022-06-23T16:00:07.143Z","updated_at":"2025-02-25T14:08:56.594Z","phase":"Phase 1/2","brief_title":"Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors","source_id_and_acronym":"NCT05429502","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MYCN • SMARCB1","pipe":" | ","alterations":" IDH wild-type","tags":["MYCN • SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Kisqali (ribociclib) • topotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 231","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 10/15/2027","primary_completion_date":" 10/15/2027","study_txt":" Completion: 01/28/2028","study_completion_date":" 01/28/2028","last_update_posted":"2025-02-17"},{"id":"80ed7c63-7fb5-4c5d-85cd-7d59cce7c2c5","acronym":"CAROLEEN","url":"https://clinicaltrials.gov/study/NCT06830720","created_at":"2025-02-25T14:20:53.607Z","updated_at":"2025-02-25T14:20:53.607Z","phase":"","brief_title":"A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence","source_id_and_acronym":"NCT06830720 - CAROLEEN","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Kisqali (ribociclib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 3250","initiation":"Initiation: 02/09/2025","start_date":" 02/09/2025","primary_txt":" Primary completion: 05/31/2030","primary_completion_date":" 05/31/2030","study_txt":" Completion: 05/31/2030","study_completion_date":" 05/31/2030","last_update_posted":"2025-02-17"},{"id":"e36e7d0b-dea5-4fa8-afc8-fa11a5c8624f","acronym":"ASPIRE","url":"https://clinicaltrials.gov/study/NCT03691493","created_at":"2021-01-18T18:05:38.724Z","updated_at":"2025-02-25T14:07:17.394Z","phase":"Phase 2","brief_title":"Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis","source_id_and_acronym":"NCT03691493 - ASPIRE","lead_sponsor":"Emory University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/08/2019","start_date":" 02/08/2019","primary_txt":" Primary completion: 10/13/2022","primary_completion_date":" 10/13/2022","study_txt":" Completion: 10/13/2022","study_completion_date":" 10/13/2022","last_update_posted":"2025-02-17"},{"id":"63510ff8-29e3-41f2-bed7-9104cb9c93b1","acronym":"PALLAS","url":"https://clinicaltrials.gov/study/NCT02513394","created_at":"2021-01-17T17:11:10.182Z","updated_at":"2025-02-25T14:39:31.455Z","phase":"Phase 3","brief_title":"PALbociclib CoLlaborative Adjuvant Study","source_id_and_acronym":"NCT02513394 - PALLAS","lead_sponsor":"Alliance Foundation Trials, LLC.","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5796","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 11/01/2020","primary_completion_date":" 11/01/2020","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-02-14"},{"id":"dc4d04a6-0615-4ba1-8e7e-f73bd8437cb0","acronym":"CAAA603B12101","url":"https://clinicaltrials.gov/study/NCT05870579","created_at":"2023-05-23T16:06:09.074Z","updated_at":"2025-02-25T14:42:04.037Z","phase":"Phase 1","brief_title":"[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer","source_id_and_acronym":"NCT05870579 - CAAA603B12101","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • fulvestrant • goserelin acetate • AAA603"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 11/13/2023","start_date":" 11/13/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 01/26/2032","study_completion_date":" 01/26/2032","last_update_posted":"2025-02-14"},{"id":"c5c6214b-5158-4684-8fe9-74226f7c6e70","acronym":"","url":"https://clinicaltrials.gov/study/NCT03439735","created_at":"2021-01-18T16:57:58.769Z","updated_at":"2025-02-25T15:10:45.531Z","phase":"Phase 2","brief_title":"Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC","source_id_and_acronym":"NCT03439735","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/20/2018","start_date":" 07/20/2018","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-13"},{"id":"3d2a4107-6ea8-46a6-9838-84fd8db8b88b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02760030","created_at":"2021-01-18T13:32:06.217Z","updated_at":"2025-02-25T15:17:17.770Z","phase":"Phase 2","brief_title":"Endocrine Therapy Fulvestrant \u0026 Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients with Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02760030","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 02/16/2017","start_date":" 02/16/2017","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2025-02-12"},{"id":"2e5ccca8-120c-4e72-b9c4-3d96418121c2","acronym":"NCI-2018-01218","url":"https://clinicaltrials.gov/study/NCT03065387","created_at":"2021-01-18T15:06:02.917Z","updated_at":"2025-02-25T15:25:34.097Z","phase":"Phase 1","brief_title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","source_id_and_acronym":"NCT03065387 - NCI-2018-01218","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • KRAS • ERBB3 • ERBB4","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification","tags":["HER-2 • KRAS • ERBB3 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Ibrance (palbociclib) • everolimus • Nerlynx (neratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 10/31/2017","start_date":" 10/31/2017","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-10"},{"id":"96089508-6422-493f-82c5-12ed65ed1d61","acronym":"ELCIN","url":"https://clinicaltrials.gov/study/NCT05596409","created_at":"2022-10-27T15:58:31.639Z","updated_at":"2025-02-25T16:33:10.407Z","phase":"Phase 2","brief_title":"ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study","source_id_and_acronym":"NCT05596409 - ELCIN","lead_sponsor":"Stemline Therapeutics, Inc.","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orserdu (elacestrant)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/19/2023","start_date":" 05/19/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-02-07"},{"id":"d6077c21-17bb-4f1e-9fd6-5e8d472b76ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03854903","created_at":"2021-01-18T19:01:32.210Z","updated_at":"2025-02-25T16:37:21.932Z","phase":"Phase 1","brief_title":"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor","source_id_and_acronym":"NCT03854903","lead_sponsor":"Georgetown University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 01/09/2025","study_completion_date":" 01/09/2025","last_update_posted":"2025-02-06"},{"id":"0d7fca80-0420-4ead-a6c7-20e34e32d1a2","acronym":"pionERA Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06065748","created_at":"2023-10-04T16:11:25.824Z","updated_at":"2025-02-25T16:47:04.424Z","phase":"Phase 3","brief_title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","source_id_and_acronym":"NCT06065748 - pionERA Breast Cancer","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER • CDK4","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation","tags":["HER-2 • ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 1050","initiation":"Initiation: 12/11/2023","start_date":" 12/11/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-02-05"},{"id":"5b3bbfcb-81b9-4094-b5ab-f48bff41c08a","acronym":"NCI-2022-04099","url":"https://clinicaltrials.gov/study/NCT05372640","created_at":"2022-05-13T12:54:24.439Z","updated_at":"2025-02-25T16:46:03.280Z","phase":"Phase 1","brief_title":"Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors","source_id_and_acronym":"NCT05372640 - NCI-2022-04099","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NUTM1","pipe":"","alterations":" ","tags":["NUTM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-05"},{"id":"4b0f1350-ce19-4057-8fd9-f2b662d41e4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06025747","created_at":"2023-09-06T14:09:40.441Z","updated_at":"2025-02-25T16:55:17.296Z","phase":"Phase 1","brief_title":"Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma","source_id_and_acronym":"NCT06025747","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" MDM2 • CDK4","pipe":" | ","alterations":" CDK4 amplification","tags":["MDM2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 02/09/2025","start_date":" 02/09/2025","primary_txt":" Primary completion: 03/03/2025","primary_completion_date":" 03/03/2025","study_txt":" Completion: 03/03/2026","study_completion_date":" 03/03/2026","last_update_posted":"2025-02-04"},{"id":"593bd291-2adc-49c4-bd0f-7562aaaad9cd","acronym":"RIBOLARIS","url":"https://clinicaltrials.gov/study/NCT05296746","created_at":"2022-03-26T00:55:02.980Z","updated_at":"2025-02-25T15:54:25.627Z","phase":"Phase 2","brief_title":"Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer","source_id_and_acronym":"NCT05296746 - RIBOLARIS","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • cyclophosphamide • Kisqali (ribociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 1100","initiation":"Initiation: 05/03/2022","start_date":" 05/03/2022","primary_txt":" Primary completion: 10/01/2029","primary_completion_date":" 10/01/2029","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2025-02-04"},{"id":"93cce817-ed7e-442e-95cd-47f76d702a46","acronym":"","url":"https://clinicaltrials.gov/study/NCT02159755","created_at":"2021-01-18T10:03:07.008Z","updated_at":"2025-02-25T16:51:23.872Z","phase":"Phase 1","brief_title":"Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma","source_id_and_acronym":"NCT02159755","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CCND1 • CD5","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 05/20/2014","start_date":" 05/20/2014","primary_txt":" Primary completion: 06/25/2018","primary_completion_date":" 06/25/2018","study_txt":" Completion: 01/20/2026","study_completion_date":" 01/20/2026","last_update_posted":"2025-02-04"},{"id":"b4375855-bbf2-4799-83aa-03c121a7f1f7","acronym":"ToPCourT","url":"https://clinicaltrials.gov/study/NCT06027268","created_at":"2023-09-07T16:09:45.091Z","updated_at":"2025-02-25T16:19:05.553Z","phase":"Phase 2","brief_title":"Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT06027268 - ToPCourT","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • gemcitabine • Cosela (trilaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/10/2024","start_date":" 01/10/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-02-04"}]